Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG2006 neoadjuvant mFOLFOX6 versus FOLFOXIRI for resectable locally advanced colon cancer
jRCTs031210365Phase 2Active, not recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Nov 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin, fluorouracil, folinic acid and irinotecan in colon cancer (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Tumor Regression Score 0-2 rate. Started Nov 2021; status: active, not recruiting.
02
Drugs
oxaliplatinfluorouracilfolinic acidirinotecan
03
Conditions
colon cancer
Beyond the preview
Go deeper on jRCTs031210365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210365.